B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Gross Margin
Bioton SA

35.4%
Current
41%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
35.4%
=
Gross Profit
62.9m
/
Revenue
177.6m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
PL
Bioton SA
WSE:BIO
241.3m PLN
35%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
317.9B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.7B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country PL
Market Cap 241.3m PLN
Gross Margin
35%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 317.9B USD
Gross Margin
67%
Country US
Market Cap 141.7B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 104.9B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.4B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Bioton SA
Glance View

Market Cap
241.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
2.83 PLN
Undervaluation 1%
Intrinsic Value
Price
B

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
35.4%
=
Gross Profit
62.9m
/
Revenue
177.6m
What is the Gross Margin of Bioton SA?

Based on Bioton SA's most recent financial statements, the company has Gross Margin of 35.4%.